{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:24:56Z","timestamp":1784921096440,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T00:00:00Z","timestamp":1455494400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland (DE)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00702-016-1519-4","type":"journal-article","created":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T09:26:31Z","timestamp":1455528391000},"page":"401-406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson\u2019s disease"],"prefix":"10.1007","volume":"123","author":[{"given":"Thomas","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Trommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Muhlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard K.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"1519_CR1","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.neuint.2012.12.004","volume":"62","author":"GF Allen","year":"2013","unstructured":"Allen GF, Ullah Y, Hargreaves IP, Land JM, Heales SJ (2013) Dopamine but not l-dopa stimulates neural glutathione metabolism. Potential implications for Parkinson\u2019s and other dopamine deficiency states. Neurochem Int 62:684\u2013694","journal-title":"Neurochem Int"},{"key":"1519_CR2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.euroneuro.2010.04.010","volume":"20","author":"A Antonini","year":"2010","unstructured":"Antonini A, Bondiolotti G, Natuzzi F, Bareggi SR (2010) Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. Eur Neuropsychopharmacol 20:683\u2013687","journal-title":"Eur Neuropsychopharmacol"},{"key":"1519_CR3","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.celrep.2015.02.048","volume":"10","author":"E Demicheva","year":"2015","unstructured":"Demicheva E, Cui YF, Bardwell P, Barghorn S, Kron M, Meyer AH, Schmidt M, Gerlach B, Leddy M, Barlow E, O\u2019Connor E, Choi CH, Huang L, Veldman GM, Rus H, Shabanzadeh AP, Tassew NG, Monnier PP, Muller T, Calabresi PA, Schoemaker H, Mueller BK (2015) Targeting repulsive guidance molecule A to promote regeneration and neuroprotection in multiple sclerosis. Cell Rep 10:1887\u20131898","journal-title":"Cell Rep"},{"key":"1519_CR4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jchemneu.2006.06.001","volume":"32","author":"H Doya","year":"2006","unstructured":"Doya H, Ito T, Hata K, Fujitani M, Ohtori S, Saito-Watanabe T, Moriya H, Takahashi K, Kubo T, Yamashita T (2006) Induction of repulsive guidance molecule in neurons following sciatic nerve injury. J Chem Neuroanat 32:74\u201377","journal-title":"J Chem Neuroanat"},{"key":"1519_CR5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1083\/jcb.200508143","volume":"173","author":"K Hata","year":"2006","unstructured":"Hata K, Fujitani M, Yasuda Y, Doya H, Saito T, Yamagishi S, Mueller BK, Yamashita T (2006) RGMa inhibition promotes axonal growth and recovery after spinal cord injury. J Cell Biol 173:47\u201358","journal-title":"J Cell Biol"},{"key":"1519_CR6","doi-asserted-by":"crossref","first-page":"e66639","DOI":"10.1371\/journal.pone.0066639","volume":"8","author":"C Jugel","year":"2013","unstructured":"Jugel C, Ehlen F, Taskin B, Marzinzik F, M\u00fcller T, Klostermann F (2013) Neuropathy in Parkinson\u2019s disease patients with intestinal levodopa infusion versus oral drugs. PLoS One 8:e66639","journal-title":"PLoS One"},{"key":"1519_CR7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4161\/cam.20167","volume":"6","author":"B Key","year":"2012","unstructured":"Key B, Lah GJ (2012) Repulsive guidance molecule A (RGMa): a molecule for all seasons. Cell Adh Migr 6:85\u201390","journal-title":"Cell Adh Migr"},{"key":"1519_CR8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.neuroscience.2010.04.079","volume":"169","author":"PD Koeberle","year":"2010","unstructured":"Koeberle PD, Tura A, Tassew NG, Schlichter LC, Monnier PP (2010) The repulsive guidance molecule, RGMa, promotes retinal ganglion cell survival in vitro and in vivo. Neuroscience 169:495\u2013504","journal-title":"Neuroscience"},{"key":"1519_CR9","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/tx200082h","volume":"24","author":"EA Liedhegner","year":"2011","unstructured":"Liedhegner EA, Steller KM, Mieyal JJ (2011) Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson\u2019s disease. Chem Res Toxicol 24:1644\u20131652","journal-title":"Chem Res Toxicol"},{"key":"1519_CR10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.molbrainres.2004.09.014","volume":"134","author":"KA Maguire-Zeiss","year":"2005","unstructured":"Maguire-Zeiss KA, Short DW, Federoff HJ (2005) Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson\u2019s disease? Brain Res Mol Brain Res 134:18\u201323","journal-title":"Brain Res Mol Brain Res"},{"key":"1519_CR11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1586\/ern.13.50","volume":"13","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T (2013) Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson\u2019s disease. Expert Rev Neurother 13:707\u2013718","journal-title":"Expert Rev Neurother"},{"key":"1519_CR12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/mds.23384","volume":"26","author":"T M\u00fcller","year":"2011","unstructured":"M\u00fcller T, Muhlack S (2011) Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson\u2019s disease patients. Mov Disord 26:543\u2013546","journal-title":"Mov Disord"},{"key":"1519_CR13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00702-013-1155-1","volume":"121","author":"T M\u00fcller","year":"2014","unstructured":"M\u00fcller T, Muhlack S (2014) Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson\u2019s disease patients. J Neural Transm 121:643\u2013648","journal-title":"J Neural Transm"},{"key":"1519_CR14","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00702-006-0442-5","volume":"113","author":"T M\u00fcller","year":"2006","unstructured":"M\u00fcller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D (2006) Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa\/carbidopa with and without entacapone in patients with Parkinson\u2019s disease. J Neural Transm 113:1441\u20131448","journal-title":"J Neural Transm"},{"key":"1519_CR15","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00702-011-0614-9","volume":"118","author":"T M\u00fcller","year":"2011","unstructured":"M\u00fcller T, Jugel C, Ehret R, Ebersbach G, Bengel G, Muhlack S, Klostermann F (2011) Elevation of total homocysteine levels in patients with Parkinson\u2019s disease treated with duodenal levodopa\/carbidopa gel. J Neural Transm 118:1329\u20131333","journal-title":"J Neural Transm"},{"key":"1519_CR16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/WNF.0b013e318283fa18","volume":"36","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T, Jugel C, Muhlack S, Klostermann F (2013) Methyl group-donating vitamins elevate 3-O-methyldopa in patients with Parkinson disease. Clin Neuropharmacol 36:52\u201354","journal-title":"Clin Neuropharmacol"},{"key":"1519_CR17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00702-014-1308-x","volume":"122","author":"T M\u00fcller","year":"2015","unstructured":"M\u00fcller T, Barghorn S, Luetge S, Haas T, Mueller R, Gerlach B, Ohm G, Eilert K, Trommer I, Mueller BK (2015) Decreased levels of repulsive guidance molecule A in association with beneficial effects of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. J Neural Transm 122:841\u2013848","journal-title":"J Neural Transm"},{"key":"1519_CR18","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","volume":"287","author":"Parkinson Study Group","year":"2002","unstructured":"Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653\u20131661","journal-title":"JAMA"},{"key":"1519_CR19","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2174\/0929867043364775","volume":"11","author":"P Riederer","year":"2004","unstructured":"Riederer P, Lachenmayer L, Laux G (2004) Clinical applications of MAO-inhibitors. Curr Med Chem 11:2033\u20132043","journal-title":"Curr Med Chem"},{"key":"1519_CR20","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1021\/bi9018658","volume":"49","author":"EA Sabens","year":"2010","unstructured":"Sabens EA, Distler AM, Mieyal JJ (2010) Levodopa deactivates enzymes that regulate thiol-disulfide homeostasis and promotes neuronal cell death\u2014implications for therapy of Parkinson\u2019s disease. Biochemistry 49:2715\u20132724","journal-title":"Biochemistry"},{"key":"1519_CR21","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/j.1460-9568.2005.03962.x","volume":"21","author":"JM Schwab","year":"2005","unstructured":"Schwab JM, Conrad S, Monnier PP, Julien S, Mueller BK, Schluesener HJ (2005) Spinal cord injury-induced lesional expression of the repulsive guidance molecule (RGM). Eur J Neurosci 21:1569\u20131576","journal-title":"Eur J Neurosci"},{"key":"1519_CR22","doi-asserted-by":"crossref","first-page":"e1744","DOI":"10.1038\/cddis.2015.109","volume":"6","author":"AP Shabanzadeh","year":"2015","unstructured":"Shabanzadeh AP, Tassew NG, Szydlowska K, Tymianski M, Banerjee P, Vigouroux RJ, Eubanks JH, Huang L, Geraerts M, Koeberle PD, Mueller BK, Monnier PP (2015) Uncoupling Neogenin association with lipid rafts promotes neuronal survival and functional recovery after stroke. Cell Death Dis 6:e1744","journal-title":"Cell Death Dis"},{"key":"1519_CR23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.freeradbiomed.2013.05.001","volume":"62","author":"M Smeyne","year":"2013","unstructured":"Smeyne M, Smeyne RJ (2013) Glutathione metabolism and Parkinson\u2019s disease. Free Radic Biol Med 62:13\u201325","journal-title":"Free Radic Biol Med"},{"key":"1519_CR24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/syn.21629","volume":"67","author":"T Tao","year":"2013","unstructured":"Tao T, Xu G, Si CC, Feng J, Kong Y, Qin X (2013) Minocycline promotes axonal regeneration through suppression of RGMa in rat MCAO\/reperfusion model. Synapse 67:189\u2013198","journal-title":"Synapse"},{"key":"1519_CR25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","volume":"54","author":"AL Whone","year":"2003","unstructured":"Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ (2003) Slower progression of Parkinson\u2019s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54:93\u2013101","journal-title":"Ann Neurol"},{"key":"1519_CR26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.biopha.2008.01.017","volume":"62","author":"GD Zeevalk","year":"2008","unstructured":"Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson\u2019s disease: is this the elephant in the room? Biomed Pharmacother 62:236\u2013249","journal-title":"Biomed Pharmacother"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-016-1519-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-016-1519-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-016-1519-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:30:35Z","timestamp":1559089835000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-016-1519-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,15]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["1519"],"URL":"https:\/\/doi.org\/10.1007\/s00702-016-1519-4","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,15]]}}}